Analysts’ Weekly Ratings Updates for DexCom (DXCM)

by · The Markets Daily

Several brokerages have updated their recommendations and price targets on shares of DexCom (NASDAQ: DXCM) in the last few weeks:

  • 10/30/2026 – DexCom had its “strong-buy” rating reaffirmed by Raymond James Financial. They now have a $97.00 price target on the stock, up from $94.00.
  • 10/30/2026 – DexCom had its price target raised by Canaccord Genuity Group from $90.00 to $97.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – DexCom had its price target raised by UBS Group from $102.00 to $107.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – DexCom had its price target raised by JPMorgan Chase & Co. from $82.00 to $85.00. They now have a “neutral” rating on the stock.
  • 10/30/2026 – DexCom had its price target raised by Barclays from $115.00 to $120.00. They now have an “overweight” rating on the stock.
  • 10/26/2026 – DexCom had its price target lowered by Leerink Partners from $94.00 to $87.00. They now have an “outperform” rating on the stock.
  • 10/13/2026 – DexCom was given a new $100.00 price target by Mizuho.
  • 10/12/2026 – DexCom had its price target raised by BTIG Research from $90.00 to $96.00. They now have a “buy” rating on the stock.
  • 10/7/2026 – DexCom had its price target raised by Evercore from $90.00 to $110.00. They now have an “outperform” rating on the stock.
  • 10/7/2026 – DexCom was upgraded by Barclays to “strong-buy”.
  • 10/6/2026 – DexCom is now covered by Barclays. They set an “overweight” rating and a $115.00 price target on the stock.
  • 10/6/2026 – DexCom was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
  • 10/1/2026 – DexCom had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $105.00 price target on the stock, up from $90.00.
  • 9/18/2026 – DexCom was given a new $102.00 price target by Truist Financial. They now have a “buy” rating on the stock.
  • 9/18/2026 – DexCom had its “buy” rating reaffirmed by TD Cowen. They now have a $95.00 price target on the stock.
  • 9/6/2026 – DexCom was upgraded by Wall Street Zen from “hold” to “buy”.

DexCom Stock Up 6.6%

Shares of NASDAQ:DXCM traded up $5.46 during trading on Wednesday, hitting $88.43. The stock had a trading volume of 5,248,232 shares, compared to its average volume of 5,025,737. The company has a market capitalization of $32.98 billion, a PE ratio of 34.68, a PEG ratio of 1.40 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.74 and a debt-to-equity ratio of 0.49. The firm’s fifty day moving average is $85.51 and its 200 day moving average is $74.79. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59.

DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 earnings per share. Analysts anticipate that DexCom, Inc. will post 2.68 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Jereme M. Sylvain sold 3,638 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the company’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $78.62, for a total transaction of $201,660.30. Following the completion of the sale, the executive vice president directly owned 120,913 shares in the company, valued at $9,506,180.06. This represents a 2.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 22,822 shares of company stock worth $1,920,193. Corporate insiders own 0.28% of the company’s stock.

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.

Read More